https://www.selleckchem.com/products/tak-779.html
https://www.selleckchem.com/products/tak-779.html
KLRD1, FOSL2 and LILRB3 while potential biomarkers for plaques progression within acute myocardial infarction as well as stable vascular disease. The mean heart doses for the FB and DIBH plans were 1.56 Gy and 0.75 Gy, respectively, a relative reduction of 47%. There were significant differences in all heart dosimetric parameters (p less then 0.001). For patients with a high heart dose in the FB plan, a relative reduction of the mean heart dose correlated with inspiratory volume (r